MIST - Milestone Pharmaceuticals GAAP EPS of -$0.35 beats by $0.05 revenue of $1M

2023-05-11 09:05:07 ET

• Milestone Pharmaceuticals press release ( NASDAQ: MIST ): Q1 GAAP EPS of -$0.35 beats by $0.05 .
• Revenue of $1M.
• As of March 31, 2023, Milestone had cash, cash equivalents, and short-term investments of $101.0 million and 33.4 million common shares issued and outstanding, with an additional 9.6 million common shares issuable upon exercise of pre-funded warrants.
• Cash resources as of March 31, 2023, together with strategic March 2023 financing, expected to fund operations into mid-2025.

For further details see: